Trials / Completed
CompletedNCT02705469
A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 1 Safety and Tolerability Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 44 (estimated)
- Sponsor
- Zenith Epigenetics · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open label, Phase 1, dose escalation and dose confirmation study of ZEN003694 in patients with mCRPC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ZEN003694 |
Timeline
- Start date
- 2016-05-01
- Primary completion
- 2017-10-01
- Completion
- 2017-10-01
- First posted
- 2016-03-10
- Last updated
- 2017-11-20
Locations
8 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02705469. Inclusion in this directory is not an endorsement.